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Background
MPS is a group of metabolic diseases caused by deficiency
of lysosomal enzymes that degrade glycosaminoglycans
(GAG). Recurrent respiratory infections, sleep distur-
bances, upper and lower airway obstruction are frequently
reported in MPS’ patients. However, cellular accumulation
of GAG fragments leading to progressive multi-system
manifestations can clutter homeostasis also modify the
function of other cellular components, their signals and
produce substances. The aim of study is to evaluate immu-
nologically MPS’ patients to clarify why they are prone to
infections.
Methods
Eighteen MPS patients (mean age = 13 yr-old, from 5 to
32 years) in enzyme replacement therapy (ERT), 88%
male were evaluated (type I = 5, type II = 9 and type
VI = 4) by measurement of complete blood count
(CBC) and quantitative/ qualitative serum immunoglo-
bulins (Ig; G, M and A) and review of their immuniza-
tion schedules (BCG, hepatitis B and rubella).
Results
All patients had previous history of wheezing and pneu-
monia that had significant improvement after initiation of
ERT. Only one patient had iron deficiency anemia. Two
patients had neutrophils lower than expected and all
patients had adequate number of lymphocytes. All patients
were vaccinated for BCG, however one patient had lymph-
node tuberculosis. Only one patient had IgG serum levels
lower than 3rd percentile. Three patients had IgM levels
3rdlower percentile. Despite complete hepatitis B vaccina-
tion schedule, 10 (55%) patients showed absence of
response to vaccine; and 1 patient (5.5%) showed no
response to rubella vaccine .
Conclusions
The immunological evaluation of MPS patients is manda-
tory, especially for the high frequency of respiratory infec-
tions presented by them. More studies on the humoral
and innate immunity are needed to understand the disease
and improve the treatment of these complications.
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